Although signs of carcinoma, NSCLC, may be present, these signs are nonspecific and can be easily overlooked. The most significant factors associated with NSCLC are smoking history, age, race, and history of prior cancer. The most significant factors associated with poor survival after lung cancer were smoking and the presence of a solid tumor on chest radiography or computed tomographic scan. The stage of NSCLC is a more significant factor with worse prognosis.
This article was based on the work of many authors. The authors and journal to which it refers have approved its reuse under appropriate agreement.
In our patient series, there was no significant difference in the rate of progression or survival between patients whose disease had been cured and those whose disease did not. In short, the disease can be controlled, but has not yet been cured.
The carcinoma, nonsmall-cell, lung may have the following cause: genetic predisposition, environmental factors (i.e., smoking), or a combination of the above. If no significant family history of disease or known environmental disease-causing factors can be proved, the possibility of genetic predisposition should be further investigated, particularly the gene loci involved in the familial transmission of this disease in twins. The exact gene(s) that contributes to the disease remains undefined.
around 25,000 new cases of carcinoma, non-small-cell lung will be diagnosed in 2022. More than 50% of these cases will be seen in people who are younger than 40 years of age, most commonly in women and males.
The majority of patients, however, obtain good and sustained quality of life, despite poor performance status and poor lung function. In addition, there was also a trend toward improved survival in those who were treated with chemotherapy. As a whole, our experience suggests that the clinical management of carcinoma, non-small-cell lung may be more complex than is currently appreciated.
To our knowledge, this is the first review of published trials of tepotinib. There are presently trials that assess the best option in different population subgroups.
This analysis supports the "one-step" hypothesis of LS spread at a time when the infiltrating carcinoma is small and the metastatic distance close to the primary site is short.
Cancer Research is the largest and most comprehensive peer-reviewed journal devoted to human cancer research. It covers advances of all types, and readers rely on it not just for reviews of a new class of drugs.
Findings from a recent study, we examined the most recent development of tepotinib and the mechanisms behind resistance. The most important mechanism is amplification of epidermal growth factor receptor (EGFR) and its downstream PI3K/Akt/mTOR cascades conferring cross-resistance to EGFR inhibitors. Further research must determine whether these mechanisms can be overcome.